Cargando…
MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression
A recent study by Limagne et al.(1) in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficac...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784763/ https://www.ncbi.nlm.nih.gov/pubmed/35106515 http://dx.doi.org/10.1016/j.xcrm.2021.100506 |